Contingency, ending period, for business combination or asset acquisition.

No definition available.

Name:	srdx_AcquisitionContingencyPeriodEndingYear
Namespace Prefix:	srdx_
Data Type:	xbrli:gYearItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset acquisition contingency period ending year.

+ References

No definition available.

+ Details

Name:	srdx_AssetAcquisitionContingencyPeriodEndingYear
Namespace Prefix:	srdx_
Data Type:	xbrli:gYearItemType
Balance Type:	na
Period Type:	duration

- Definition

Asset acquisition contingent payments upon achievement of regulatory milestones.

+ References

No definition available.

+ Details

Name:	srdx_AssetAcquisitionContingentPaymentsUponAchievementOfRegulatoryMilestones
Namespace Prefix:	srdx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Asset acquisition installment payment period.

+ References

No definition available.

+ Details

Name:	srdx_AssetAcquisitionInstallmentPaymentPeriod
Namespace Prefix:	srdx_
Data Type:	xbrli:gYearItemType
Balance Type:	na
Period Type:	duration

- Definition

Gross, contractual value of cash consideration to be transferred at a future date, if contingencies are met, by the acquirer to the former owners of the acquiree in a business combination.

+ References

No definition available.

+ Details

Name:	srdx_BusinessCombinationContingentConsiderationContractual
Namespace Prefix:	srdx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Gross, contractual value of cash consideration to be transferred at a future date by the acquirer to the former owners of the acquiree in a business combination.

+ References

No definition available.

+ Details

Name:	srdx_BusinessCombinationDeferredConsiderationContractual
Namespace Prefix:	srdx_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Number of installment payments for cash consideration to be transferred at a future date by the acquirer to the former owners of the acquiree in a business combination.

+ References

No definition available.

+ Details

Name:	srdx_BusinessCombinationDeferredConsiderationContractualNumberInstallments
Namespace Prefix:	srdx_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Commitments and contingencies.

+ References

No definition available.

+ Details

Name:	srdx_CommitmentsAndContingenciesLineItems
Namespace Prefix:	srdx_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Future cash outflow to pay for purchases of fixed assets that have occurred.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-4

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-3

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482913/230-10-50-5

+ Details

Name:	us-gaap_CapitalExpendituresIncurredButNotYetPaid
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479581/805-30-50-1

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireBusinessesGross
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=srdx_VetexMedicalLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_StatementScenarioAxis=srt_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=srdx_EmbolitechLLCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies - Additional Information (Detail) $ in Millions	3 Months Ended			6 Months Ended	12 Months Ended					24 Months Ended
	Sep. 30, 2027 USD ($)	Sep. 30, 2024 USD ($)	Dec. 31, 2023 USD ($)	Mar. 31, 2024	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($) Installment	Sep. 30, 2020 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2024 USD ($)
Vetex Medical Limited [Member]
Commitments And Contingencies [Line Items]
Consideration paid at closing							$ 39.9
Deferred consideration payment, number of installment \| Installment							2
Contingent consideration, contractual value							$ 3.5
Contingency period ending year							2027
Forecast [Member] \| Vetex Medical Limited [Member]
Commitments And Contingencies [Line Items]
Deferred consideration, contractual value	$ 1.8	$ 1.8
Embolitech LLC [Member]
Commitments And Contingencies [Line Items]
Contingent payments upon achievement of regulatory milestones			$ 1.0
Installment payment period				2024
In Process Research and Development \| Embolitech LLC [Member]
Commitments And Contingencies [Line Items]
Contingency period ending year			2033
Payments to acquire in-process research and development					$ 1.0	$ 0.5	$ 1.0	$ 1.0	$ 5.0
In Process Research and Development \| Embolitech LLC [Member] \| Forecast [Member]
Commitments And Contingencies [Line Items]
Contractual obligation payable in fiscal 2024										$ 0.9